Charles Schwab Portfolio holdings
Charles Schwab Corporation, founded in 1971 by Charles R. Schwab and headquartered in Westlake, Texas, is a leading financial services firm that revolutionized retail investing by offering low-cost brokerage services. Initially disrupting the industry with discount commissions, it has grown into a powerhouse providing a wide array of services, including trading platforms, robo-advisors, retirement accounts, and banking products, managing hundreds of billions in client assets. Known for its user-friendly technology and customer-centric approach, Schwab caters to individual investors, financial advisors, and institutions, notably expanding through its 2020 acquisition of TD Ameritrade. With a mission to democratize investing, Charles Schwab remains a dominant force in the shift toward accessible, self-directed wealth management.
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
iShares 1-5 Year Investment Grade Corporate Bond ETF
IGSB
|
+$596M |
| 2 |
Vanguard Intermediate-Term Treasury ETF
VGIT
|
+$429M |
| 3 |
Verizon
VZ
|
+$399M |
| 4 |
Amgen
AMGN
|
+$214M |
| 5 |
Citizens Financial Group
CFG
|
+$212M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
iShares MBS ETF
MBB
|
+$561M |
| 2 |
iShares National Muni Bond ETF
MUB
|
+$535M |
| 3 |
Oracle
ORCL
|
+$144M |
| 4 |
State Street Financial Select Sector SPDR ETF
XLF
|
+$143M |
| 5 |
Vanguard Mortgage-Backed Securities ETF
VMBS
|
+$141M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Technology | 20.17% |
| 2 | Financials | 13.07% |
| 3 | Healthcare | 12.05% |
| 4 | Consumer Discretionary | 10.98% |
| 5 | Industrials | 9.25% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
3151
Viemed Healthcare
VMD
$451M
| $533K | ﹤0.01% |
74,413
-553
| -0.7% | -$4.79K |
|
3152
Brookfield Renewable
BEPC
$6.04B
| $531K | ﹤0.01% |
12,650
-262,673
| -95% | -$11.2M |
|
|
HOFV
3153
DELISTED
Hall of Fame Resort & Entertainment Co
HOFV
| $531K | ﹤0.01% |
6,136
+5,300
| +634% | +$459K |
|
3154
Nathan's Famous
NATH
$403M
| $529K | ﹤0.01% |
7,416
+720
| +11% | +$48K |
|
3155
Kinetik
KNTK
$3.68B
| $528K | ﹤0.01% |
+15,616
| New | +$494K |
|
|
SEEL
3156
DELISTED
Seelos Therapeutics, Inc. Common Stock
SEEL
| $528K | ﹤0.01% |
52
+46
| +767% | +$756K |
|
3157
Alkami Technology
ALKT
$1.91B
| $527K | ﹤0.01% |
+14,756
| New | +$541K |
|
3158
Global Water Resources
GWRS
$209M
| $527K | ﹤0.01% |
30,851
-1,956
| -6% | -$33.2K |
|
|
RTB
3159
RTB Digital
RTB
$226M
| $527K | ﹤0.01% |
+126
| New | +$531K |
|
|
ONCT
3160
DELISTED
Oncternal Therapeutics, Inc. Common Stock
ONCT
| $521K | ﹤0.01% |
5,484
+4,691
| +592% | +$557K |
|
3161
Tiptree Inc
TIPT
$655M
| $519K | ﹤0.01% |
55,701
-5,935
| -10% | -$62.6K |
|
|
HBMD
3162
DELISTED
Howard Bancorp, Inc. Common Stock
HBMD
| $518K | ﹤0.01% |
32,095
-139
| -0.4% | -$2.3K |
|
|
OPTN
3163
DELISTED
OptiNose
OPTN
| $511K | ﹤0.01% |
10,950
-5,587
| -34% | -$285K |
|
3164
Adicet Bio
ACET
$84.7M
| $510K | ﹤0.01% |
+3,098
| New | +$631K |
|
3165
Cyclerion Therapeutics
CYCN
$15.2M
| $506K | ﹤0.01% |
6,481
-3,503
| -35% | -$219K |
|
|
BMTX
3166
DELISTED
BM Technologies, Inc.
BMTX
| $504K | ﹤0.01% |
43,364
| – | – |
|
3167
iShares Russell 1000 Value ETF
IWD
$81.8B
| $500K | ﹤0.01% |
3,150
-650
| -17% | -$103K |
|
3168
BeyondSpring
BYSI
$46.5M
| $496K | ﹤0.01% |
47,461
+6,915
| +17% | +$72.9K |
|
3169
HF Foods Group
HFFG
$80.2M
| $496K | ﹤0.01% |
93,756
| – | – |
|
3170
iRadimed
IRMD
$1.22B
| $496K | ﹤0.01% |
16,863
+1,140
| +7% | +$31.4K |
|
3171
Avalo Therapeutics
AVTX
$1.03B
| $494K | ﹤0.01% |
52
+7
| +16% | +$58.6K |
|
|
KZR
3172
DELISTED
Kezar Life Sciences
KZR
| $489K | ﹤0.01% |
9,001
+1,369
| +18% | +$77.7K |
|
3173
NextCure
NXTC
$20.5M
| $489K | ﹤0.01% |
5,073
-3,101
| -38% | -$317K |
|
|
PZN
3174
DELISTED
Pzena Investment Management, Inc. Class A
PZN
| $488K | ﹤0.01% |
44,276
+4,044
| +10% | +$44.6K |
|
|
EXTN
3175
DELISTED
Exterran Corporation
EXTN
| $488K | ﹤0.01% |
102,461
-65,271
| -39% | -$279K |
|
Similar funds
Charles Schwab's Q2 2021 Portfolio in Review
As of Q2 2021, Charles Schwab held 3,648 positions worth $301B, up 10% from $273B the previous quarter. Its ten largest holdings account for 17% of the portfolio.
Charles Schwab's Q2 2021 filing shows 163 new, 2,481 increased, 676 reduced and 240 closed positions. Its largest new stake was Vanguard Intermediate-Term Treasury ETF: 6,338,757 shares worth $430M. The largest sale was iShares MBS ETF, an estimated $561M.
By sector, the portfolio is most concentrated in Technology at 20% of assets, up from 20% a quarter earlier, followed by Financials and Healthcare.
- Charles Schwab's largest Q2 2021 buy was Vanguard Intermediate-Term Treasury ETF: 6,338,757 shares worth $430M.
- Charles Schwab added most to iShares 1-5 Year Investment Grade Corporate Bond ETF in Q2 2021, an estimated $596M increase.
- Charles Schwab's biggest Q2 2021 reduction was iShares MBS ETF, cutting an estimated $561M.
- Charles Schwab fully exited Invesco S&P 500 Low Volatility ETF in Q2 2021, selling an estimated $92.7M.
- Charles Schwab's ten largest holdings make up 17% of its $301B portfolio in Q2 2021.
- Charles Schwab opened 163 new positions and closed 240 in Q2 2021.
- Charles Schwab's portfolio value rose 10% quarter-over-quarter to $301B.
Based on Charles Schwab's 13F filing for Q2 2021, filed 16 Aug 2021.